Scinovex
article Open AccessTop 1% cited

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

Journal of Medical Genetics · 2009 · Vol. 46(4) · pp. 266–271
Elizabeth Berry‐KravisDavid HesslSarah M. CoffeyCrystal HerveyAndrea SchneiderJohn M. YuhasJohn A. HutchisonMike SnapeMichael R. TranfagliaDanh V. NguyenRandi J. Hagerman

Abstract

Clinically significant adverse effects were not identified in this study of single dose fenobam across the range of dosages utilised. The positive effects seen in animal models of FXS treated with fenobam or other mGluR5 antagonists, the apparent lack of clinically significant adverse effects, and the potential beneficial clinical effects seen in this pilot trial support further study of the compound in adults with FXS.

Genetics and Neurodevelopmental DisordersAutism Spectrum Disorder ResearchEpigenetics and DNA MethylationDosingMedicineAdverse effectPharmacokineticsFragile X syndromeDoseClinical trialCeiling effectInternal medicinePharmacology

MeSH terms

Administration, OralAdolescentAdultChromatography, LiquidFemaleFragile X SyndromeHumansImidazolesInhibition, PsychologicalMaleNeural InhibitionNeuropsychological TestsPilot ProjectsMass SpectrometryReceptors, Metabotropic Glutamate

Funding

  • FRAXA Research Foundation
  • National Institutes of Health
  • National Center for Research Resources
Citations
410
FWCI
38.00
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
Cited by
Neurodevelopmental model of schizophrenia: update 2012
Molecular Psychiatry · 2012 · 778 citations
References
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome · Scinovex